News

RECENT NEWS

Medexus Files Business Acquisition Report

Posted on January 7, 2019

MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report (“BAR”) on SEDAR (www.sedar.com) in relation to the previously announced transaction that occurred on October 16, 2018. “As can be seen in the unaudited interim financial statements (non-IFRS compliant) for the period ended Sept 30, 2018 included in the BAR, both Medexus Inc. and medac Pharma […]

Read more >
Medexus Announces New Chief Executive Officer, Chair of the Board of Directors, Other Organizational Updates and Equity Incentive Grants

Posted on December 17, 2018

MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: PDP, OTCQB: PDDPF) today announced organizational changes designed to better position the Company as it continues to integrate the transformative acquisitions of Medexus Inc. (“Medexus”) and medac Pharma, Inc. (“Medac Pharma”). ORGANIZATIONAL AND CORPORATE UPDATES The Company is pleased to announce that the board of directors of the Company (the “Board”) has appointed Ken d'Entremont […]

Read more >
Pediapharm Announces Name Change, Consolidation and Debenture Repayment

Posted on December 13, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the "Company") (TSXV: PDP, OTCQB: PDDPF) is pleased to announce that at the annual general and special meeting of shareholders held on December 12, 2018 (the "Meeting"), the Company's shareholders approved the change […]

Read more >
Pediapharm Announces Q2 Results – Record Adjusted EBITDA, Record Revenue and 13th Consecutive Year-Over-Year Quarterly Revenue Growth

Posted on November 27, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Nov. 27, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSXV: PDP, OTCQB: PDDPF) is pleased to file its second quarter financial […]

Read more >
Pediapharm Announces Closing of Transformative Acquisitions, Diversifying and Expanding the Platform for Future Growth

Posted on October 17, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Oct. 16, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV: PDP, OTCQB: PDDPF) is pleased to announce the closing of its previously announced acquisitions […]

Read more >
Pediapharm Announces Closing of Subscription Receipt Offering for Total Gross Proceeds of $62 Million

Posted on October 12, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Oct. 11, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV: PDP, OTCQB: PDDPF) is pleased to announce the closing today of its previously announced […]

Read more >
Pediapharm Files Corporate Presentation

Posted on September 12, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Sept. 12, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV:PDP) (OTCQX:PDDPF) announces that, further to its press release issued on September 6, 2018, it […]

Read more >
Pediapharm Announces Transformative Acquisitions and $60 Million Offering of Subscription Receipts

Posted on September 7, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements […]

Read more >
Pediapharm Announces Q1 Results – Record Revenue and 12th Consecutive Year-Over-Year Quarterly Growth

Posted on September 4, 2018

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Aug. 27, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE: PDP) (OTCQB: PDDPF) is pleased to file its first quarter financial results ended June 30, 2018. All dollar amounts are expressed in Canadian currency and results are […]

Read more >
Pediapharm Announces Annual Audited Financial Results – 61% Annual Revenue Growth and 11th Consecutive Year-over-year Quarterly Growth

Posted on July 18, 2018

MONTRÉAL, July 18, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP) (OTCQB:PDDPF) is pleased to announce its annual audited results for the year ended March 31, 2018. All dollar amounts are expressed in Canadian currency and results are reported in accordance with IFRS accounting principles. KEY HIGHLIGHTS – PERIOD ENDED MARCH […]

Read more >
Pediapharm Announces the Commercial Launch of Cuvposa™ in Canada

Posted on April 3, 2018

MONTREAL, April 03, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP) (OTCQB:PDDPF) is very pleased to announce the Canadian commercial launch of Cuvposa™ (Glycopyrrolate oral solution 1 mg/ 5 mL) which is indicated to reduce chronic severe drooling in patients aged 3-18 years with neurologic conditions associated with problem drooling (e.g. […]

Read more >
Pediapharm Announces Q3 Results – 10th Consecutive Year-over-year Quarterly Growth

Posted on February 27, 2018

MONTREAL, QUEBEC–(Marketwired – Feb. 27, 2018) – NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP)(OTCQB:PDDPF) is pleased to file its third quarter financial results ended December 31, 2017. All dollar amounts are expressed in Canadian currency and results are reported in […]

Read more >
Pediapharm Announces Extension of Debentures and Warrants

Posted on January 31, 2018

MONTREAL, QUEBEC–(Marketwired – Jan. 31, 2018) – NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP)(OTCQB:PDDPF) has proposed to amend its existing convertible secured debentures (the “Debentures”) and common share purchase warrants (“Warrants”) issued on March 30, 2015 with a maturity date […]

Read more >
Pediapharm Announces Q2 Record Revenue and First-Ever Adjusted Ebitda Positive Quarter

Posted on November 28, 2017

MONTREAL, QUEBEC–(Marketwired – Nov. 27, 2017) NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pediapharm Inc. (TSX VENTURE:PDP)(the “Company” or “Pediapharm”) is pleased to file its second quarter financial results ended September 30, 2017. All dollar amounts are expressed in Canadian currency and results are reported in accordance with […]

Read more >